Strides' US Revenues Soar, Recovery Strategy ‘Executing To Plan’

Strides Pharma “very confident” about future after Indian generic company’s fourth-quarter US revenues rocketed 181% and EBITDA margins beat market expectations.

Steps
STRIDES' US REVENUES GROW SHARPLY • Source: Shutterstock

After posting strong fourth-quarter earnings, Strides Pharma Science Ltd founder and group chief executive Arun Kumar said the company’s fortunes "are now resurgent" thanks to a “major strategy reset” focused on growing US revenues and an exit from Australia.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip